

This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

BUSY WEEK? Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director *Patricia Van Arnum*.

Sponsored By:



spectrum
CHEMICAL MFG. CORP.
800.772.8786
SpectrumChemical.com

Spectrum Offers 1200+ USP/NF cGMP Products.
Order Your 2016 USP Catalog!

[Click Here](#)



1. [Pfizer Announces Executive Leadership for the Combined Allergan and Pfizer](#)

Pfizer has announced the executive leadership team for the combined Pfizer and Allergan following the close of the proposed \$160 billion combination of the two companies, which is expected to close in the second half of 2016. [Read More](#)

2. [Mylan To Acquire Swedish Specialty Pharma Company Meda for \\$7.2 Billion](#)

Mylan N.V. has recommended a public offer to the shareholders of Meda Aktiebolag, a Swedish specialty pharmaceutical company, to tender all their shares in Meda to Mylan for SEK 165 (\$19.5) per Meda share for a total equity value of approximately SEK 60.3 billion (\$7.2 billion). [Read More](#)

3. [Hikma Lowers Purchase Price For BI's Roxane by \\$535 Million](#)

Hikma Pharmaceuticals is revising the purchase price it had offered to acquire Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc., two businesses of Boehringer Ingelheim, based on a lower-than-expected financial performance by Roxane in 2015 and anticipated for 2016 and 2017. Hikma will reduce its purchase price by \$535 million to a gross consideration of \$647 million as opposed to the \$1.18 billion it offered in July 2015. [Read More](#)

4. [FDA Advisory Committee Recommends Pfizer's Biosimilar of Remicade](#)

A FDA advisory committee has recommended to approve Pfizer's investigational biosimilar, infliximab, the first biosimilar monoclonal antibody therapy to be reviewed by the FDA for licensure in the US. The drug is a biosimilar of Johnson & Johnson's Remicade, for which J&J posted 2015 global sales of \$6.6 billion and US sales of \$4.5 billion. [Read More](#)

5. [Sandoz Acquires European Rights to Biosimilar of Remicade](#)

Sandoz, the generics arm of Novartis, has acquired from Pfizer the rights for the development and commercialization of an investigational biosimilar of infliximab in the 28 countries that form the European Economic Area. Although retaining US rights, Pfizer had to divest the European rights to infliximab as part of the European Commission's approval of Pfizer's \$17 billion acquisition of Hospira in 2015. [Read More](#)

6. [FDA Issues Warning Letter to Ipca Laboratories](#)

The US Food and Drug Administration has posted a Warning Letter to Ipca Laboratories for violations of current good manufacturing practices (cGMP) based on inspections of three facilities of the company in India made in 2014 for data integrity issues. [Read More](#)

7. [FDA Seeks 8% Funding Increase in FY 2017 Budget](#)

The US Food and Drug Administration is requesting a total budget of \$5.1 billion as part of the President's fiscal year (FY) 2017 budget, an 8% increase over the enacted budget for FY 2016. The

overall request includes a net increase of \$14.6 million in budget authority and \$268.7 million in user fees. [Read More](#)

8. [EU Introduces New Regulation for Safety Features Against Falsified Medicines](#)

The European Medicines Agency and the European Commission have prepared an implementation plan for centrally authorized medicines to guide applicants and marketing-authorization holders in meeting the requirements of a new regulation of the Falsified Medicines Directive. The plan introduces two safety features, a unique identifier (a 2-dimension barcode) and an anti-tampering device, to be placed on the packaging of most medicines for human use. [Read More](#)

9. [Strides Shasun To Acquire Stakes in African, Australian Companies](#)

Strides Shasun, a vertically integrated pharmaceutical company based in Bangalore, India, has agreed to acquire controlling stakes in two companies, one focused in Africa and the other in Australia. [Read More](#)

10. [AAI Pharma Services Corp./Cambridge Major Laboratories Expands Sterile Manufacturing](#)

AAI Pharma Services Corp./Cambridge Major Laboratories, Inc. has expanded sterile fill-finish capabilities and capacity in its Charleston, South Carolina site. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

[Forward this email](#)



This email was sent to esanders@dcat.org by dcatnews@dcat.org | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe™](#) | [About our service provider.](#)

Drug, Chemical, & Associated Technologies Association | One Union Street | Suite 208 | Robbinsville | NJ | 08691